An active surveillance, post-authorization safety study (PASS) of serious infection, malignancy, cardiovascular and other safety events of interest among patients treated with tofacitinib for moderately to severely active rheumatoid arthritis within the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis (BSRBR-RA) (Safety of tofacitinib in BSRBR-RA)

ENCePP Code of conduct

No

Data sources

• Data source(s):
  British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
• Data source(s), other:
  BSRBR - Rheumatic and Musculoskeletal conditions
• Data sources (types):
  Disease registry

  Other
• Data sources (types), other:
  Prospective patient-based data collection, Prescription event monitoring

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No